PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

The TAVR is a real, true, bona fide miracle of modern medicine. And it isn’t simple at all.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

In the United States, cardiovascular health is especially important. Heart disease is the leading cause of death in the U.S., and as many as 1.5 million people have been diagnosed with aortic stenosis ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

ROCK ISLAND, Ill. (KWQC) - Hundreds of people have had a severe heart valve problems treated in the Quad Cities. UnityPoint Health is celebrating its 600th person to successfully receive a TAVR in the ...

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...